drugset / Trial / NCT04833959
Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
NaSingle-groupOpen-labelDiagnostic
Summary
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.
Timeline
- Start
- 2021-03-26
- Primary completion
- 2024-03
- Completion
- 2024-03
Outcome
Outcome not reported
Stopped (Business): “Business Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 89Zr-panitumumab | Diagnostic / imaging agent | 37 mbq | — |